【摘要】 目的:探讨P53蛋白在乳腺浸润性导管癌新分子分型中表达及其临床意义。方法:采用免疫组织化学方法 (二步法)检测92例乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)、Ki-67和P53蛋白的表达,并进行新的分子分型及与P53蛋白相关性分析。结果:乳腺浸润性导管癌P53蛋白阳性表达率为53.3%,正常乳腺组织表达为阴性,两者比较差异有统计学意义(P<0.05)。HER-2过表达型和ER、PR、Ki-67三阴性型中P53蛋白阳性率明显高于Luminal A型、Luminal B1型、Luminal B2型,两者比较差异有统计学意义(P<0.05)。此外,乳腺淋巴结转移与P53蛋白呈正相关(r2=0.413,P<0.01)。结论:临床在使用ER、PR、HER-2、Ki-67四种指标对乳腺浸润性导管癌进行分型时同时检测P53蛋白,有助于评估肿瘤的生物学行为及预后。更多还原

【Abstract】 Objective:To investigate the expression of P53 protein in new molecular classification of breast cancer and clinical significance.Methods:Estrogen receptor(ER),progestrone receptor(PR),human epidermal receptor 2(HER-2),Ki-67 and P53 expression were performed by immunohistochemical staining in 92 surgical specimens of ductal breast carcinoma.The correlation between P53 expression and new molecular classification of breast cancer was analyzed.Results:P53 was negative in normal breast tissues while positive in 53.3% cases of breast cancer(P<0.05);The positive rate of P53 in HER-2 overexpression and triple-negative breast cancer was significantly higher than that those of Luminal A and B subtypes(P<0.05).Conclusion:Clinically,molecular classification of breast infiltrative ductal carcinoma via four items as ER,PR,HER-2,and ki-67 as well as detection of P53 are helpful for the assessment of tumor biological behavior and prognosis.更多还原